The von Hippel-Lindau tumor suppressor protein (pVHL) suppresses tumor formation by binding the a subunits of hypoxia-inducible factors (HIFs) responsible for stimulating tumor angiogenesis and glycolysis, targeting them for ubiquitination and proteasomal destruction. Loss of pVHL leads to the development of sporadic renal cell carcinomas (RCCs). In the present study, we sought to determine whether engineered overexpression of pVHL in tumors other than RCC can inhibit tumor growth, either as a monotherapy, or in combination with antisense HIF-1a therapy. Intratumoral injection of subcutaneous EL-4 thymic lymphomas with an expression plasmid encoding pVHL resulted in the downregulation of HIF-1a and vascular endothelial growth factor (VEGF). There was a concomitant reduction in tumor angiogenesis and increased tumor cell apoptosis due in part to downregulation of Bcl-2 expression. VHL therapy resulted in the complete regression of small (0.1 cm diameter) tumors whereas, in contrast, large (0.4 cm diameter) EL-4 tumors were only slowed in their growth. Nevertheless, large tumors completely regressed in response to intratumoral injection of a combination of antisense HIF-1a and VHL plasmids. Combination therapy resulted in increased losses of HIF-1a, VEGF, and tumor blood vessels, and increased tumor cell apoptosis. These novel results suggest that synergistic therapies that simultaneously block the expression or function of HIF-1a, and enhance the expression or function of VHL may be beneficial in the treatment of cancer.
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant familial cancer syndrome that predisposes affected individuals to a variety of highly vascular tumors. 1, 2 The most common tumors are hemangioblastomas of the central nervous system, renal cell carcinoma (RCC), and pheochromocytoma. VHL kindreds have germline mutations in VHL, and somatic inactivation or loss of the remaining wild-type VHL allele is linked to tumor formation.
pVHL is a tumor suppressor, whose functional inactivation stimulates tumor formation in a variety of ways, in particular by increasing the stability of HIF-1. 2, 3 HIF-1 regulates cellular adaption to changes in oxygen availability by regulating genes involved in angiogenesis, erythropoiesis, energy and iron metabolism, tissue matrix metabolism, and cell survival decisions; which are the key factors for tumor growth and survival. [4] [5] [6] [7] HIF-1 is an ab heterodimer whose b subunit is expressed constitutively and is not significantly affected by hypoxia, whereas levels of the a subunit rise markedly with hypoxia, and fall rapidly under normoxic conditions. A 35 amino-acid subdomain of the a domain of the 30 kDa pVHL binds elongin C, which recruits additional proteins including elongin B, cullin-2, the RING-H2 protein Rbx1/Roc1, and ubiquitin-conjugating enzyme E2, to form a ubiquitinating complex. The b domain of pVHL binds hypoxia-inducible factor (HIF) a subunits HIF-1a and HIF-2a, targeting them for ubiquitination and proteasomal destruction in a pVHL a-domain-dependent manner. 8 The binding of HIF-1a subunits to pVHL, and their rapid degradation by the pVHL ubiquitinating complex under normoxic conditions, is regulated by oxygen and iron-dependent hydroxylation of Pro-402 and Pro-564 within HIF-1a, [9] [10] [11] mediated by a novel HIF1a-prolyl-hydroxylase. The hydroxylase acts as an oxygen sensor, requiring Fe 2 þ as a cofactor, as well as O 2 and 2-oxoglutarate as cosubstrates for activity. 11 The hydroxylase hydroxylates Pro-402 and Pro-564 under normoxic conditions enabling VHL to bind to HIF-1a, and mediate its destruction, whereas it is inactive under hypoxia preventing VHL from binding to HIF-1a, and thereby rendering HIF-1 stable. Oxygen-dependent regulation of HIF activity is mediated by hydroxylation of conserved asparagine residues. The asparaginyl hydroxylase, factor-inhibiting HIF-1 (FIH-1), hydroxylates Asn-803 in the C-terminal transactivation domain (CTAD) of HIF thereby preventing CTAD from associating with transcriptional coactivators under normoxic conditions. 12, 13 In terms of mechanisms underlying VHL disease, mutation of the a and b domains of pVHL prevents formation of a pVHL ubiquitinating complex and/or binding to HIF-1, respectively, leading to stabilization of HIF-1.
3,8 A hypoxic phenotype results in which increased levels of HIF-1 induce the synthesis of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), platelet-derived growth factor, and glucose transporter-1 (Glut-1), which assist tumor growth by stimulating tumor angiogenesis, and metabolism. [14] [15] [16] [17] Reintroduction of wild-type VHL into the VHLnegative tumor RCC in which both VHL alleles are either inactivated or lost, restores pVHL-mediated functions, and leads to a loss of tumorigenicity in nude mice. 18 Here, we examine whether the beneficial affects of VHL therapy can be extended beyond the treatment of RCC tumors. We ask whether engineered overexpression of pVHL in EL-4 tumors unrelated to RCCs can lead to the inhibition of tumor growth. We also determine whether this approach might synergize with antisense HIF-1a therapy, which we have previously shown to have beneficial affects capable of causing the complete eradication of small tumors. 19 
Results
Engineered overexpression of pVHL induces the complete regression of small tumors It could not be predicted with certainty whether overexpressed pVHL would downregulate HIF-1 pathways, and angiogenesis in tumors other than RCC. In tumors, pVHL not only has to contend with HIF-1 induced by hypoxia, but also HIF-1 induced in response to tumorderived factors such as v-src, and insulin-like growth factor-1 receptor (IGF-1R) ligands (IGF-I, IGF-II, and insulin). 20, 21 To test the latter notion, small EL-4 tumors, 0.1 cm in diameter, were established in the right flank of C57BL/6 mice, and injected with a DNA/liposome transfection vehicle containing either 100 mg of empty pCDNA3, VHL-pCDNA3, or antisense HIF-1a-pCDNA3 plasmids. The latter reagent, has previously been shown to eradicate tumors completely. 19 Tumors grew rapidly following injection of empty pCDNA3 plasmid, reaching 1 cm in size within 12 days. In contrast, tumors injected with either VHL or antisense HIF-1a plasmid rapidly regressed within 1 week of injection, and completely disappeared ( Figure 1a) . The effects did not appear to be due to an inherent toxicity of overexpressed VHL for cells growing under normoxic conditions, as tumor cells harvested from tumors transfected with VHL, antisense HIF-1a, and empty vector control had similar growth rates in vitro (Figure 1d ).
Overexpressed pVHL can only slow the growth of large tumors
We have previously demonstrated that tumors become increasingly refractory to antiangiogenic gene therapy as they increase in size. 19, 22 Thus, while antisense HIF-1a therapy is able to eradicate small tumors, it could only delay the growth of larger 0.4 cm diameter tumors (Figure 1b) . To determine the utility of VHL therapy in combating larger tumors, 0.4 cm diameter tumors were injected with 100 mg of the VHL pCDNA3 plasmid. Injection of VHL plasmid led to overexpression of pVHL, whereas tumors injected with empty plasmid displayed low levels of endogenous pVHL (Figure 2a) . Note, as reported previously, 23 that tumor cells form almost the entire cellular content of EL-4 tumors, and hence the vast majority of cells that stain are tumor cells. Injection of antisense HIF-1a plasmid into tumors had no detectable effect on the expression level of endogenous pVHL, but as expected reduced the levels of HIF-1a (Figure 2b) . These results were confirmed by Western blot analysis of lysates of tumor cells extracted from tumors, which revealed that exogenous pVHL was overexpressed twofold and was of the expected size of 20 kDa (Figure 2d) . Injection, as above, of 0.4 cm diameter tumors with 100 mg of VHL plasmid failed to eradicate tumors, but nevertheless the tumor growth rate was significantly (Po0.01) reduced (30%), to an extent similar to that achieved with antisense HIF-1a (Figure 1b) . The failure of VHL therapy is not the result of an inadequate dosage of VHL plasmid, as increasing the dosage to 250 mg did not significantly (P40.05) improve the inhibition of tumor growth ( Figure 1c ). All tumors eventually reached 1 cm in diameter within 2.5 weeks, and mice had to be euthanased.
pVHL synergizes with antisense HIF-1a to induce the complete regression of large tumors It was possible that overexpressed pVHL might synergize with antisense HIF-1a to eradicate tumors, as the affects of pVHL are not limited to regulating HIF-1a levels and angiogenesis, but include regulation of the cell cycle, apoptosis, and the extracellular matrix. In order to test this notion, we injected large 0.4 cm diameter tumors with 100 mg of each of the VHL and antisense HIF-1a plasmids. The VHL plasmid was injected first, followed by the HIF-1a antisense plasmid 48 h later, as our previous experience has indicated that for whatever reason simultaneous injection of two different plasmids 
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VHL and antisense HIF-1a cancer gene therapy Figure  3d ) distances to the nearest CD31-labelled venules from an array of points within tumors treated with VHL or antisense HIF-1a plasmid were significantly (both Po0.05) longer than those for tumors treated with empty vector. However, the combination of VHL and antisense HIF-1a was the most effective of all, such that only a few pinpoints of CD31 staining, presumably representing small malformed vessels, were apparent ( Figure 3a) . The median and 90th centile distances to the nearest CD31-labelled venules from an array of points within tumors treated with the combination of VHL and antisense HIF1a plasmid were significantly longer than those for tumors treated with either empty pCDNA3 (Po0.01), VHL (Po0.05), or antisense HIF-1a (Po0.05) plasmid (Figure 3c and d) , respectively. Since tumors were deprived of tumor blood vessels, and survival factors, we examined whether they underwent programmed death as measured by in situ labelling of fragmented DNA using the TUNEL method. A small VHL and antisense HIF-1a cancer gene therapy X Sun et al number of apoptotic cells were detected in tumors injected with empty plasmid (Figure 4a ), whereas tumor apoptosis was almost doubled following injection of either VHL or antisense HIF-1a plasmids (Figure 4a , and refer to Apoptosis Index (AI) in Figure 4b ). Despite the finding that antisense HIF-1a was superior at inhibiting tumor angiogenesis, VHL treatment was more effective at inducing tumor apoptosis, but once again the combination of VHL and antisense HIF-1a was the most effective (Figure 4a and b) . Thus, the AI for tumors injected with VHL, antisense HIF-1a, or a combination of the latter two plasmids was significantly (Po0.001) different from that of tumors treated with empty pCDNA3 vector. The AI for tumors injected with a combination of VHL and antisense HIF-1a plasmids was significantly different from that of tumors injected with either VHL (Po0.05) or antisense HIF-1a (Po0.01) plasmid.
Since EL-4 cells express the antiapoptotic factor Bcl-2, 24, 25 we wished to examine whether VHL-induced apoptosis may be due in part to the ability of overexpressed VHL to downregulate the expression of Bcl-2. As shown in Figure 4c , overexpression of VHL by intratumoral injection of VHL plasmids led to a 40% .) to the nearest CD31-labelled venules from an array of points within tumors. Tumors were injected with either empty pcDNA3 plasmid, VHL plasmid, antisense HIF-1a (aHIF) plasmid, or a combination of VHL and aHIF plasmids as indicated. n, number of tumors assessed. Tumor blood vessels stained with the anti-CD31 mAb were counted in five blindly chosen random fields to record mean blood vessel counts per section ( Â 40 magnification field). A significant (Po0.01) difference in mean vessel counts, median, or 90th centile distances to nearest blood vessels between tumors injected with therapeutic plasmid vectors versus tumors injected with empty pCDNA3 plasmid is denoted by an asterisk.
VHL and antisense HIF-1a cancer gene therapy X Sun et al decrease in the expression of Bcl-2, compared with levels of Bcl-2 present in empty plasmid-injected tumors. In contrast, antisense HIF-1a had little or no affect on Bcl-2 expression, which may partly explain the fact that VHL treatment was more effective at inducing tumor apoptosis than was antisense HIF-1a. Tumor cell homogenates were prepared from tumors as in (a) that had been injected with empty plasmid, or plasmids encoding either VHL or antisense HIF-1a. They were resolved by SDS-PAGE, and Western blotted with an antibody against Bcl-2. Band density was quantified using Scion Image software. 23 Our studies demonstrate that EL-4 cells are not immunogenic per se in being able to stimulate an adaptive immune response, and HIF-1a and VHL are not known to be immunomodulatory.
VHL might have been expected to exert greater antiangiogenic activity than that of antisense HIF-1a, as it is known to target HIF-2a in addition to HIF-1a; a property which could explain the synergy between VHL and antisense HIF-1a in combating tumor angiogenesisz However it did not, suggesting that if HIF-2a is present, it probably has little affect on EL-4 tumor angiogenesis. Rather, VHL therapy was more effective at inducing tumor cell apoptosis than was antisense HIF-1a. pVHL may have a predominant role in regulating cell growth and survival, in addition to its role in regulating angiogenesis. It has previously been reported that EL-4 tumors express the antiapoptotic factors Bcl-2 24 and survivin. 23 We have shown here that overexpressed VHL specifically downregulates Bcl-2 expression, which may partly explain the fact that VHL treatment was more effective at inducing tumor apoptosis than was treatment with antisense HIF-1a. A number of other potentially tumor-suppressive and proapoptotic properties of pVHL have also been reported. Thus, pVHL assists in the assembly of a fibronectin matrix (which can suppress cellular properties associated with malignancy), 27 induces RCC cells to differentiate and undergo growth arrest; [28] [29] [30] [31] stabilizes actin organization, increases cell adhesion, and inhibits cell motility and invasiveness of tumor cells. 32 pVHL downregulates the expression of hnRNP A2, which leads to a decrease in Glut-1 mRNA, 33 inhibition of tumor glycolysis, and decreased tumor metabolism. It suppresses tumor cell invasion (and angiogenesis) by upregulating the expression of urokinase-type plasminogen activator mRNA and protein and conversely downregulating the expression of plasminogen activator 1 mRNA and protein. 34 In recent studies aimed at unravelling VHL-dependent pathways, it was discovered that the role of VHL as a tumor suppressor was more complex than previously thought, that some VHL target genes were not regulated by oxygen, and that tumor cells have evolved both VHL-dependent and -independent mechanisms to respond to hypoxic stress. 35, 36 Nevertheless, it is probable that the decreased tumor growth, and increased tumor cell apoptosis observed following overexpression of VHL largely reflects increased oxygen and nutrient starvation, due to downregulation of HIF-1a and tumor angiogenesis. VHL post-transcriptionally downregulates the expression of VEGF, 37 in addition to destabilizing HIF-1a. It has been reported that loss of VHL in VHL-deficient gene knockout mice is sufficient not only to stabilize HIF-1a subunits under normoxia, but also to fully activate HIF-1-mediated responses, 38 hence maintaining and enhancing the VHL pathway is critical to preventing tumor angiogenesis. Antisense HIF-1a not only downregulates HIF-1a, but also destabilizes VEGF mRNA. 7 We have demonstrated here that the combination of antisense HIF-1a and VHL therapies leads to an almost complete loss of tumor angiogenesis compared to monotherapies, resulting in the complete regression of large tumors. Unlike conventional antiangiogenic agents, antisense HIF-1a and VHL therapies inhibit an array of signalling pathways, some unrelated to angiogenesis. We propose that the combined affect of inhibiting these several pathways is enough to cripple tumor cells, depriving them of key factors required for growth and survival. While the present study has focused on intratumoral VHL and antisense HIF-1a gene transfer into localized tumors, it will be appreciated that systemic means of delivery, including viral vectors, would provide greater utility for this therapeutic strategy, in particular for patients with systemic disease.
Materials and methods

Mice and cell lines
Male C57BL/6 mice, 6-8 weeks old, were obtained from the Animal Resource Unit, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand. The EL-4 thymic lymphoma, which is of C57BL/6(H-2 b ) origin, was purchased from the American Type Culture Collection (Rockville, MD, USA). It was cultured at 371C in DMEM medium (Gibco BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum, 50 U/ml penicillin/streptomycin, 2 mM L-glutamine, and 1 mM pyruvate.
Expression plasmids
A cDNA fragment encoding full-length (546 bp) mouse VHL was PCR amplified using IMAGE clone 63956 as a template and the primers 5 0 -AGG CGG CGG GGG AGC CCG GTC CTG AGG AGA TGG AGG CTG GGC GGC CGC GGC CGG TGC TGC GCT CG-3 0 and 5 0 -ACT CTC AAG GTG CTC TTG GCT CAG TCG CTG TAT GTC CTT CCG CAC ACT TGG GTA G -3 0 . The resulting PCR product was used as a template for further amplification with the primers 5 0 -GGG AAT TCC AAT AAT GCC CCG GAA GGC AGC CAG TCC AGA GGA GGC GGC GGG GGA GCC CGG TCC TG-3 0 and 5 0 -GGT CTA GAT CAA  GGC TCC TCT TCC AGG TGC TGA CTC TCA AGG  TGC TCT TGG CTC A-3 0 . The PCR product was subcloned into pCDNA3 (Invitrogen). An antisense pCDNA3 expression vector encoding the 5 0 -end of HIF1a (nucleotides 152-454; GenBank AF003698) has been VHL and antisense HIF-1a cancer gene therapy X Sun et al described previously. 19 All constructs were verified by DNA sequence analysis.
Gene transfer of expression plasmids in situ and measurement of antitumor activity
Purified plasmids were diluted to 1 mg/ml in a solution of 5% glucose in 0.01% Triton X-100, and mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany), as described previously. 39 Tumors were established by injection of 2 Â 10 5 EL-4 tumor cells into the right flank of mice, and growth was determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accord with Animal Ethics Approval (University of Auckland). Once tumors reached either 0.1 or 0.4 cm in diameter, they were injected with 100 ml expression plasmid (100 mg). The larger tumors (0.4 cm in diameter) were injected at multiple sites to help distribute the plasmid. We have previously demonstrated that similar or identical transfection efficiency is obtained when injecting 0.1 and 0.4 cm diameter tumors with 60 and 100 mg plasmid, respectively, in 100 ml transfection vehicle. 40 Empty pCDNA3 vector served as a control reagent. For combination treatments, reagents were delivered in a timed fashion, where VHL plasmid was injected first, followed by antisense HIF-1a plasmid 48 h later. Two injections were also given in monotherapy controls in combinational studies. Thus, mice received two intratumoral injections of VHL plasmid for VHL monotherapy and two injections of antisense HIF-1a plasmid for antisense HIF-1a monotherapy, administered in a timed fashion as for the combination of VHL þ HIF-1a. Empty pCDNA3 vector served as a control reagent, and when used for combination therapy was injected twice in a timed fashion, as for therapeutic plasmids. To determine plasmid dosage-dependency, VHL plasmid concentration was adjusted to 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg/ml, and 100 ml plasmid-liposome vehicle injected. All experiments included six mice per group, and each experiment was repeated at least once.
Immunohistochemistry
Tumor cryosections (10 mm) prepared 2 days following injection of plasmids were incubated overnight with either a rabbit polyclonal antibody against a peptide corresponding to N-terminal amino acids 1-181 of VHL (FL-181, Santa Cruz Biotechnology, Inc), a mouse antimouse HIF-1a mAb (H1a67, Novus Biologicals, Inc., Littleton, CO, USA), or a rabbit polyclonal antibody against VEGF (Ab-1, Lab Vision Corporation, CA, USA). Rabbit antibody-stained sections were subsequently incubated for 30 min with appropriate secondary antibodies (VECTASTAIN Universal Quick kit, Vector Laboratories, Burlingame, CA, USA), and developed with Sigma FAST DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) and CoCl 2 enhancer tablets (Sigma). Sections were counterstained with Mayer's hematoxylin. The Vector M.O.M. Immunodetection Kit (Vector Laboratories, Inc., Burlingame, CA, USA) was used to detect the mouse anti-HIF-1a mAb, as it reduces background staining. The total number of HIF-1a-positive cells in 10 randomly selected fields was counted, and the percentage of positive staining cells was calculated (percentage of positive cells¼number of positive cells Â 100/total number of cells).
Assessment of vascularity
The methodology to determine tumor vascularity has been described previously. 19, 40, 41 Briefly, 10 mm frozen tumor sections prepared 4 days after plasmid injection were immunostained with the anti-CD31 antibody MEC13.3 (Pharmingen, CA, USA). Stained blood vessels were counted in five blindly chosen random fields (0.155 mm 2 ) at Â 40 magnification, and the mean of the highest three counts was calculated. The concentric circles method 42, 43 was used to assess vascularity, where five to six tumor sections were analyzed for each plasmid-injected tumor.
Cell proliferation assay
To determine whether the therapeutic expression plasmids affected tumor cell growth in vitro, single cell suspensions of EL-4 tumors prepared following gene transfer of either VHL, antisense HIF-1a, or empty plasmid were seeded at 10 4 cells/well into 24-well culture plates in triplicate. Cells were grown in DMEM medium (Gibco BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum, 50 U/ml penicillin/ streptomycin, 2 mM L-glutamine, and 1 mM pyruvate at 371C. Cells numbers were enumerated at 24-h intervals using a hemocytometer (Improved Neubauer).
In situ detection of apoptotic cells
Serial sections of 6 mm thickness were prepared from excised tumors that had been frozen in liquid nitrogen, and stored at À701C. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick end-labelling (TUNEL) staining of sections was performed using an in situ apoptosis detection kit from Boehringer Mannheim, Germany. Briefly, frozen sections were fixed with 4% paraformaldehyde solution, permeabilized with a solution of 0.1% Triton X-100 and 0.1% sodium citrate, incubated with TUNEL reagent for 60 min at 371C, and examined by fluorescence microscopy. Adjacent sections were counterstained with hematoxylin and eosin. The total number of apoptotic cells in 10 randomly selected fields was counted. The AI was calculated as the percentage of positive staining cells, (AI¼number of apoptotic cells Â 100/total number of nucleated cells).
Western blot analysis
Tumors previously injected with either empty plasmid, or VHL and antisense HIF-1a expression plasmids were excised, minced with scissors and homogenized in protein lysate buffer (50 mmol/l Tris pH 7.4, 100 mmol/ l EDTA, 0.25 mol/l sucrose, 1% SDS, 1% NP40, 1 mg/ml leupeptin, 1 mg/ml pepstatin A and 100 mmol/l phenylmethylsulfonyl fluoride) at 41C using a motor-driven Virtus homogenizer (Virtus, Gardiner, NY, USA). Tumor lysates from each treatment group were pooled, and debris removed by centrifugation at 10 000 g for 10 min at 41C. Protein samples (100 mg) were resolved on 10% polyacrylamide SDS gels under reducing conditions, and electrophoretically transferred to nitrocellulose Hybond C extra membranes (Amersham Life Science, Buckingham, England). After blocking the membranes with 5% bovine serum albumin in Tween 20/Tris-buffered saline VHL and antisense HIF-1a cancer gene therapy X Sun et al (TTBS; 20 mmol/l Tris, 137 mmol/l NaCl pH 7.6, containing 0.1% Tween-20), blots were incubated with primary antibodies and subsequently with horseradish peroxidase-conjugated secondary antibodies. They were developed by enhanced chemiluminescence (Amersham International, Buckingham, England) and exposure to X-ray film. Band density was quantified using Scion Image software (Scion Corporation, Frederick, MD, USA). The antibody used to detect Bcl-2 was a rabbit polyclonal antibody obtained from Abcam Ltd, UK.
Statistical analysis
Results were expressed as mean values þ standard deviation (s.d.). A Student's t-test was used for evaluating statistical significance, where a value less than 0.05 (Po0.05) denotes statistical significance.
